Neoplasia/BPH

	Perioperative Outcomes of Salvage Radical Prostatectomy After Radiation Therapy: A Nationwide Analysis Using the National Clinical Database of Japan. Int J Urol Fujita K, Makita A, Ishii D, Yamamoto H, Yasui T, Kikuchi E. PMID: 42603088 [PubMed - indexed for MEDLINE]
	Survival Benefit of ARSI Therapy in Japanese mCSPC: A Systematic Review and Meta-Analysis. Int J Urol Iwamoto H, Izumi K, Hori T, Inaba T, Nakagawa R, Kamijima T, Makino T, Naito R, Yaegashi H, Shigehara K, Nohara T, Yamada Y, Shimomura T, Onishi K, Mizokami A. PMID: 42603083 [PubMed - indexed for MEDLINE]
	Decoding the role of exosomes in bladder cancer: focusing on tumor progression and immune microenvironment modulation. Front Oncol Wang X, Li Z, Zhang B. PMID: 42602585 [PubMed]
	Bladder mucosal apoptosis index and quality of life after adjuvant intravesical BCG therapy for non-muscle-invasive bladder cancer: a retrospective propensity-score-matched study. Front Oncol Zhu H, Tan S, Liu X. PMID: 42601890 [PubMed]
	Induced proximity-based therapeutics for advanced prostate cancer. NPJ Drug Discov Ching J, Chau CH, Figg WD. PMID: 42601416 [PubMed]
	Application Study of Clinical Features Combined With Ultrasound-based Radiomics Nomogram For Grading Diagnosis of Bladder Urothelial Carcinoma. Acad Radiol Zhang HP, Fu F, Fan XQ, Li ZY, Zhu YF, Zheng WT, Zhuang JJ, Chen YF, Lian GT, Lin XH, Ye Q. PMID: 42601302 [PubMed - as supplied by publisher]
	Re: Siva S, Ali M, Hardcastle N, et al. Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-Year Outcomes from a Pooled Analysis of the FASTRACK Trials. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(26)00170-1 and re: Siva S, Pryor D, Martin J, et al. Long-term Outcomes of Stereotactic Ablative Body Radiotherapy for Primary Kidney Cancer (TROG 15.03 FASTRACK II): A Multicentre, Non-randomised, Phase 2 Study. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(26)00091-4. Eur Urol Capitanio U, Bex A, Stewart GD, Larcher A, Montorsi F. PMID: 42601237 [PubMed - as supplied by publisher]
	Time toxicity in patients receiving brachytherapy and hormonal therapy for recurrent prostate cancer: a cohort study. BMJ Support Palliat Care Chow R, Bayrakdarian S, Zimmermann C, Richards GC, Heneghan C, Leigh J, Chung H. PMID: 42601182 [PubMed - as supplied by publisher]
	Risk factors for lymph node metastasis in a contemporary radical prostatectomy cohort. Am J Clin Pathol Iakymenko OA, Khosravaniardakani S, Menendez A, Sioni SR, Jorda M, Punnen S, Parekh DJ, Gonzalgo ML, Kryvenko ON. PMID: 42601052 [PubMed - indexed for MEDLINE]
	Duct Quest: An International Survey of Genitourinary and Community Pathologists Reveals Diagnostic Uncertainties in Separating Atypical Intraductal Proliferation from High-grade Prostatic Intraepithelial Neoplasia and Intraductal Carcinoma of the Prostate. Hum Pathol Bernhardt M, Bollen IF, Chan E, Cheng L, Collins K, Downes M, Greenland N, Iczkowski KA, Jufe L, Kweldam C, van Leenders G, Paner GP, Perry-Keene J, Scherping AK, Tsuzuki T, Varma M, Wiliamson SR, Wobker S, Zhou M, Zhou X, Shah RB, Kristiansen G. PMID: 42600754 [PubMed - as supplied by publisher]
	Review of Neurovascular Reconstruction During Robotic-Assisted Laparoscopic Radical Prostatectomy. Curr Urol Rep Zhang VS, Wang SL, Schurhamer B. PMID: 42599609 [PubMed - indexed for MEDLINE]
	The role of magnetic resonance imaging in the active surveillance of prostate cancer: state of the art. Abdom Radiol (NY) Testini V, Eusebi L, Sortino G, Pitoni L, Masino F, Montatore M, Guglielmi G. PMID: 42599455 [PubMed - as supplied by publisher]
	PSA density for clinically significant prostate cancer detection: a retrospective cohort study on the influence of age and prostate volume. World J Urol Engelage L, Behnel N, Lumiani A, Bashkanov O, Stadelmeier LF, Tamalunas A, Buchner A, Sroka R. PMID: 42599322 [PubMed - indexed for MEDLINE]
	Evaluation of triplet therapy combined with robot-assisted cytoreductive prostatectomy for high-volume metastatic prostate cancer: a multicentre randomised controlled trial protocol. BJU Int Yang X, He Z, Chen J, Lei H, Yan B, Chen L, Liu H, Pang J. PMID: 42598911 [PubMed - as supplied by publisher]
	Efficacy of Nivolumab in Chemotherapy-Resistant Mesothelioma of the Tunica Vaginalis Testis: A Case Report. Cancer Rep (Hoboken) Koyanagi H, Kawahara T, Inagawa N, Shiga M, Sakurai H, Yamaguchi A, Tanuma K, Nitta S, Kojo K, Shiga M, Nagumo Y, Ikeda A, Kandori S, Hoshi A, Negoro H, Kawai H, Matsubara D, Nishiyama H. PMID: 42598890 [PubMed - indexed for MEDLINE]
	Sequential Enzalutamide-Docetaxel Versus Abiraterone-Docetaxel Therapy in Castration-Resistant Prostate Cancer: A Subanalysis of the ENABLE Study. Int J Urol Kamiyama M, Izumi K, Mitsui T, Shima T, Kato Y, Mita K, Okamura T, Inoue S, Hoshi S, Tanaka N, Yoshio Y, Tatarano S, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Mizokami A. PMID: 42598868 [PubMed - indexed for MEDLINE]
	From fusion partner to clinical practice: A treatment-oriented framework for transcription factor E3 (TFE3)-rearranged renal carcinoma. Cancer Pathog Ther Man J, Wang K, Zhang Y, Wang H, Yang L. PMID: 42598106 [PubMed]
	Preliminary study on the efficacy of pazopanib combined with toripalimab as first-line therapy for metastatic renal cell carcinoma: Real-world data from a single center. Oncol Lett Wang B, Xing T, Liu H, Han X, Wu K. PMID: 42597921 [PubMed]
	Nanoplatform-Mediated Remodeling of the Immune Microenvironment in Renal Cell Carcinoma. Int J Nanomedicine Luo M, Tang P, Chen X, Lan W, Tang S, Liu Q, Zhou L, Huang Y. PMID: 42597677 [PubMed - indexed for MEDLINE]
	Beyond IMDC: do expanded models improve survival discrimination in metastatic renal cell carcinoma? A real-world cohort study. Front Oncol , Gökmen A, Haf. PMID: 42597456 [PubMed]

Articles 1 - 20 / 190500

Page 1 of 9525



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy